Answers are grounded in this paper and cite their sources.
Glioblastoma (GBM) is an aggressive brain cancer that typically results in death in the first 15 months after diagnosis. There have been limited advances in finding new treatments for GBM. In this study, we investigated molecular differences between patients with extremely short (≤9 months, Short term survivors, STS) and long survival (≥36 months, Long term survivors, LTS). Patients were selected from an in-house cohort (GLIOTRAIN-cohort), using defined inclusion criteria (Karnofsky score >70; age <70 years old; Stupp protocol as first line treatment, IDH wild type), and a multi-omic analysis of LTS and STS GBM samples was performed. Transcriptomic analysis of tumour samples identified cilium gene signatures enriched in LTSs. Immunohistochemical analysis confirmed the presence of cilia in the tumours of LTSs. Notably, reverse phase protein array analysis (RPPA) demonstrated increased phosphorylated GAB1 (Y627), SRC (Y527), BCL2 (S70) and RAF (S338) protein expression in STS compared to LTS. We identified 25 unique master regulators (MR) and 13 transcription factors (TFs) belonging to ontologies of integrin signalling and cell cycle to be upregulated in STS. These data deliver new potential biomarkers and therapeutic targets for the management of GBM.
No takes yet. Share an insight, caveat, or question.
Biswas et al. (2023) studied this question.